Canada's High Court Kills Viagra Patent In Pfizer-Teva Row

Law360, New York (November 8, 2012, 12:55 PM EST) -- The Supreme Court of Canada on Thursday voided Pfizer Inc.'s patent for erectile dysfunction treatment Viagra, finding the drugmaker didn't disclose enough about how the medicine works to deserve exclusivity and clearing the way for generic competition from Teva Pharmaceutical Industries Ltd.

In a 7-0 decision, justices faulted Pfizer for not specifically naming sildenafil citrate as Viagra’s active ingredient in a patent application approved in 1998, and said the remedy was to strip away monopoly power that had been challenged by Teva and expected to last...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.